Community Practice Connections™: Transforming Outcomes in Relapsed and Refractory Multiple Myeloma with Antibody-Based Regimens: An Interactive Case-Based Discussion

Release Date: July 30, 2021
Expiration Date: July 30, 2022

Activity Overview

The treatment landscape for patients with multiple myeloma (MM) has evolved rapidly in recent years. As novel monoclonal antibody-based therapies start to be incorporated in the frontline and relapsed settings, clinicians are frequently unsure of how to appropriately combine and sequence therapies.
 
This online educational activity is designed to provide expert commentary regarding recent clinical data on the efficacy and safety of novel monoclonal antibody therapy in patients with MM and the optimal strategies to combine and sequence monoclonal antibody therapies to enhance patient outcomes. Advances in understanding the molecular mechanism of action of monoclonal antibody therapies in MM and how this contributes to the development of prognostic and predictive biomarkers for this disease are also discussed. This activity is presented in a multimedia format that includes a series of video interviews with expert thought leaders integrated into text-based elements.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme.
 

Target Audience

This educational activity is directed toward medical oncologists and haematologists who treat patients with multiple myeloma. Fellows, nurses, nurse practitioners, physician assistants, and other healthcare professionals interested in the management of patients with multiple myeloma are also invited to participate.

Learning Objectives

Upon succesl completion of this activity, you should be better prepared to:

• Explain the mechanisms of action and clinical profiles for monoclonal antibodies which have been applied to multiple myeloma treatment
• Describe recent evidence from pivotal trials that have evaluated antibody-based combinations among patients with relapsed/refractory multiple myeloma
• Apply individual patient characteristics to stratify risk and optimize decision making in relapsed/refractory myeloma settings, including information on comorbidities and previous drug exposure
• Integrate recent clinical trial evidence on monoclonal antibodies to inform personalized treatment planning and sequencing in relapsed/refractory multiple myeloma

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible entities.

Faculty

Graham Jackson, MA, MB, BS, MD
Consultant Haematologist NCCC
Newcastle Upon Tyne Hospital Trust
Professor of Clinical Haematology
University of Newcastle Upon Tyne
Newcastle Upon Tyne, England

Disclosures: Grant Research Support: Bristol Myers Squibb, Takeda, Onyx; Consultant: Amgen, Bristol Myers Squibb, GlaxoSmithKline, Johnson & Johnson, Sanofi Genzyme, Takeda; Speakers’ Bureau: Amgen, Bristol Myers Squibb, Johnson & Johnson, Sanofi Genzyme, Takeda

Ceri Bygrave, MD
Consultant Haematologist
University Hospital of Wales
Cardiff, Wales

Disclosures: Ceri Bygrave, MD has no relevant financial relationships with ineligible companies.

Enrique M. Ocio, MD, PhD
Head of the Hematology Department
University Hospital “Marqués de Valdecilla”
Associate Professor of Medicine. University of Cantabria
Santander, Spain

Disclosures: Consultant: BMS, Sanofi, GSK, Takeda; Speakers’ Bureau: Janssen, Takeda; Other: Honoraria: Janssen, BMS, Sanofi, GSK, Oncopeptides, Amgen, Takeda

Fredrik Schjesvold, MD, PhD
Head, Oslo Myeloma Center
Oslo University Hospital
Researcher
KG Jebsen Centre for B Cell Malignancies
University of Oslo
Oslo, Norway

Disclosures: Grant/Research Support: GlaxoSmithKline, Janssen, Oncopeptides; Consultant: Amgen, Celgene/ Bristol Myers Squibb, Janssen, Novartis, Skylite DX, Oncopeptides, Sanofi Genzyme, Takeda

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.